Patents Assigned to Vaxdesign Corporation
  • Publication number: 20190187127
    Abstract: In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.
    Type: Application
    Filed: September 7, 2017
    Publication date: June 20, 2019
    Applicant: Sanofi Pasteur VaxDesign Corporation
    Inventors: Evan GOMES, Tirumalai KAMALA, Luis MOSQUERA, Vaughan WITTMAN, William WARREN, Janice MOSER, Donald DRAKE
  • Publication number: 20180292397
    Abstract: A system and method provide for high through put determination of agglutination states. The system includes a rotating table and multiple plate tilting stations. The system also includes one or more optical paths positioned to image entire plate arrays in tilted and/or untilted configurations. The system preferably includes image analysis software to analyze an image of an array of test wells and determine an agglutination state of each well based on the image analysis.
    Type: Application
    Filed: June 7, 2018
    Publication date: October 11, 2018
    Applicant: Sanofi Pasteur VaxDesign Corporation
    Inventors: Michael NGUYEN, Robert PARKHILL
  • Patent number: 8722402
    Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 13, 2014
    Assignees: Sanofi Pasteur Vaxdesign Corporation, Mount Sinai School of Medicine, The Whitehead Institute, Massachusetts Institute of Technology, The Scripps Research Institute
    Inventors: William L Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Harcohen, Bruce Torbett
  • Patent number: 8298824
    Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: October 30, 2012
    Assignee: Sanofi Pasteur Vaxdesign Corporation
    Inventors: William L. Warren, Heather Fahlenkamp, Russell G. Higbee, Eric M. Mishkin, Guzman Sanchez-Schmitz, Michael D. Rivard, Santosh Pawar
  • Patent number: 8298823
    Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: October 30, 2012
    Assignee: Sanofi Pasteur Vaxdesign Corporation
    Inventors: William L. Warren, Robert Parkhill, Michael N. Nguyen, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Russell Higbee, Donald Drake, III, Anatoly Kachurin, David Moe
  • Publication number: 20100285132
    Abstract: The present invention directs to compositions and methods for modulating immune system. One aspect of the present invention relates to a composition comprising FADD-dependent signaling pathway modulators. Another aspect of the 5 present invention relates to biodegradable microparticles, such as a chitosan microparticic, or PLGA/PEI microparticle, designed to deliver nucleic acids and/or proteins, such as FADD-dependent signaling pathway modulators, to boost different pathways of an immune response. Another aspect of the present invention relates to the method of making biodegradable microparticles. The further aspect of the present invention relates to the use of the chitosan and other polycationic microparticles to deliver FADD-dependent signaling pathway modulators to modulate immune system for the prevention and/or treatment infectious diseases and cancers.
    Type: Application
    Filed: September 18, 2009
    Publication date: November 11, 2010
    Applicants: University Of Miami, Vaxdesign Corporation
    Inventors: Russell G. Higbee, Glen N. Barber
  • Patent number: 7785806
    Abstract: The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: August 31, 2010
    Assignee: Vaxdesign Corporation
    Inventors: William L. Warren, Donald Drake, III, Janice Moser, Inderpal Singh, Haifeng Song, Eric Mishkin